Search 

Propath is a leader in Europe for histopathology and molecular pathology.  As a GLP and GCP compliant facility, our experience of regulatory and research studies spans over 30 years.

Quay Pharma is one of the world’s leading Contract Development and Manufacturing Organisations, or CDMOs. Based in the UK, we provide specialist services to the pharmaceutical and biotech industries built on our unique expertise in drug formulation development, analytical services and contract manufacturing, MHRA and FDA inspected and approved.

The integrated Pharmaceutical Development and Clinical Pharmacology Service that maximises value build.

We are based at Cheadle Royal Business Park, a centre of scientific excellence in the North of England.

By choosing Seda you can rest assured you are in safe hands. Our team have delivered high quality products, processes and regulatory submissions leading to the approval and launch of several successful medicines. We have practiced across therapeutic areas and have extensive experience in the development of Oncology drugs, including those with ‘breakthrough’ status.

Seda are pioneers of novel approaches to accelerate projects that can save you money and create better value. Our team of experts have deep scientific experience across a broad range of disciplines and stages of development, from discovery to launch.

Strategy > Design > Data > Interpretation > Execution

• Consultancy
• Physicochemical characterisation and preformulation studies
• Solid form selection including polymorphs, salts and co-crystals
• Preclinical safety study formulation development for challenging molecules
• First-time-in-clinic and later phase / commercial formulation development
• Enabling formulations and specialist drug delivery technology selection
• Preclinical DMPK
• Clinical pharmacokinetics and drug absorption including modeling
• Due diligence, competitor analysis and technology opportunity assessments
• Scientific leadership: academic - industry collaborations; training and mentoring; scientific advisory boards

Routes of administration and technology areas we cover:

Oral

• Immediate release
• Modified release
• Oral poorly solubles

Standard Injectables 

Complex Injectables

• Poorly soluble IV
• Depot
• Targeted

Nasal and Inhaled

Selcia is a leading global CRO specialising in 14C GMP radiolabelled API for clinical trials and in 14C custom radiolabelling for DMPK, dermal penetration and environmental fate studies.

Selcia offers the full range of drug discovery services; integrated drug discovery, assay development, medicinal chemistry and ADME. With specialist expertise in macrocycles, natural products and their simplification and optimisation for drug use. Selcia has a unique peptidyl prolyl isomerase (PPIase) inhibitor screening platform.

To support regulatory submissions, Selcia offers GLP analysis; including GLP NMR (500MHz), mass spectrometry, HPLC (analytical and preparative) and specialised purification capabilities from analytical (µg) to multi-100g scale.

Sharp Packaging Services works across the world to create unique commercial and clinical packaging solutions for the pharmaceutical and biotechnology industry.

We are made up of two dynamic international divisions, Sharp Packaging Solutions and Sharp Clinical Services. Together our 1,600-strong team works from state-of-the-art facilities in the United States, United Kingdom, Belgium and the Netherlands.

We’ve built an exceptional global reputation for the design, serialisation and production of innovative, cost-effective compliance packaging for even the most complex products.

Our extensive range includes blister packs, bottles, pouches and stick packs, but our expertise goes far beyond, enabling us to support your product through every stage of design, development, manufacture and delivery.

Our clinical services division is one of the world’s leading providers of innovative clinical supply chain services, with a talented and highly experienced team that can handle every aspect of your supply chain. Our work spans everything from drug development and manufacturing to clinical supplies packaging, labelling, distribution, Qualified Person auditing and comparator sourcing.

SiSaf is a Specialty Biopharmaceutical company with a unique patented next-generation Bio-adoptive silicon technology that can elegantly re-invent and solve even the most complex drug and bio-availability challenges.

An Australian headquartered biotechnology company with labs/offices in Melbourne (Australia), Cambridge (UK), San Francisco (USA) and China (Shanghai & Suzhou), SYNthesis Research has established a number of R&D collaborations which have generated novel IP which is now available for partnering. SYNthesis Research's sister company, SYNthesis med chem, is a chemistry-focussed contract research organisation that carries out custom synthesis and medicinal chemistry projects. 

TRN are an integrated team of scientific experts who provide Pharmaceutical R&D scientific consultancy, project management, outsourcing and due diligence services. Our experienced team has in depth expertise across the key drug discovery and development disciplines covering both small molecule and biotherapeutics.

TRN also collaborate with Universities and research organisations to progress promising drug discovery projects from lead identification through early clinical development. We partner with Principal Investigators and Technology Transfer groups to secure funding, provide strategic guidance and practical support to access and manage available technologies and resources worldwide. Much of this work is conducted at risk. Areas of focus are acute care, antibiotics, antivirals, neurodegeneration and CVMD.

TRN are currently working in collaboration with the University of Tennessee and the MRCT to enable the development of EmstoPA, a humanised antibody fragment for the treatment of bleeding complications in patients who have received the clot buster tPA, for the treatment of stroke or pulmonary embolism. Currently no specific tPA reversal agents are in development. The team are seeking investors to help fund the development of this exciting and innovative product. Two additional drug repurposing collaborations are in early development in the acute care arena.

Therakind, a, private pharmaceutical company, is focused on developing safe, effective, authorised speciality medicines. To date, two paediatric products have been successfully developed and commercialised and a portfolio of further products are under development in late stage development Therakind is developing a portfolio of further products. We have an earlier stage diabetic nasal product for treatment of hypoglycaemia and a pipeline of further products.

Therakind operates with several business models to generate a platform of products generating royalties and also provides consultancy in pharmaceutical development.

Touchlight’s in vitro enzymatic DNA amplification platform addresses every major limitation of pDNA fermentation. Touchlight’s platform has improved yield, speed & fidelity, no antibiotic resistance & the ability to amplify complex secondary structures.